Peptide Vaccine Therapy in Colorectal Cancer

Bartnik, Aleksandra; Nirmal, Ajit J.; Yang, Shiyu

doi:10.3390/vaccines1010001

Cited by 32 publications

(29 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the safety outcomes that were reported in other clinical studies of peptide vaccines that are currently under development, and TEAE observed here were similar to those reported in the other studies . In addition, serious adverse reactions as a result of peptide vaccine therapies are very rare . Thus, it can be suggested that OCV‐C02 at 0.3–6 mg/body has a well‐tolerable profile with no major toxic effects.…”

Section: Discussionsupporting

confidence: 91%

“…Systemic chemotherapy including 5‐fluorouracil, irinotecan and oxaliplatin are usually indicated, either in combination or sequential regimens, for these patients to reduce tumor‐related symptoms and prolong median overall survival (OS) . However, the disease is mostly incurable and often progressive as a result of chemoresistance, and chemotherapy is often associated with toxic side‐effects that affect patient's quality of life . These treatment limitations have driven the development of alternative treatment strategies with improved efficacy, safety and tolerability …”

mentioning

confidence: 99%

“…Understanding the oncogenic roles of these molecules in cancer growth and their high immunogenicity has driven the development of peptide‐based vaccines as emerging new anti‐cancer therapy . When presented on human leukocyte antigen (HLA) molecules, the antigenic peptides are recognized by specific CTL triggering the immune system to eliminate cancer cells and generate antigen‐specific immune cells that promote immune‐mediated cancer regression …”

mentioning

confidence: 99%

“…(7,8) However, the disease is mostly incurable and often progressive as a result of chemoresistance, and chemotherapy is often associated with toxic side-effects that affect patient's quality of life. (7,9) These treatment limitations have driven the development of alternative treatment strategies with improved efficacy, safety and tolerability. (10) Recently, cancer immunotherapy is gaining much attention as another treatment option for CRC.…”

mentioning

confidence: 99%

“…(11)(12)(13) When presented on human leukocyte antigen (HLA) molecules, the antigenic peptides are recognized by specific CTL triggering the immune system to eliminate cancer cells and generate antigen-specific immune cells that promote immune-mediated cancer regression. (9) OCV-C02 is a peptide vaccine, which consists of ring finger protein 43 (RNF43)-721 and translocase of outer mitochondrial membrane 34 (TOMM34)-299 peptides that were derived from two TAA expressed in CRC, RNF43 and TOMM34, respectively. (14)(15)(16) It is HLA-A*24:02-restricted, whereby this HLA class I allele has been reported to have higher frequency in certain ethnic populations including Japanese.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Phase 1 study of OCV‐C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer

et al. 2017

View full text Add to dashboard Cite

Summary OCV‐C02 is a peptide vaccine consisting of two peptide epitopes derived from ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34 (TOMM34). This Phase 1 study assessed the safety, preliminary efficacy and immunological responses following OCV‐C02 administration in patients with advanced or relapsed colorectal cancer who were intolerant or refractory to standard chemotherapy. Primary endpoint was any occurrence of dose‐limiting toxicity (DLT) during cycle 1. Secondary endpoints were treatment‐emergent adverse events, efficacy and immunological responses. Efficacy was evaluated based on overall response rate, disease control rate, time to treatment failure and overall survival. Immunological responses were evaluated by measuring CTL, delayed‐type hypersensitivity (DTH) and regulatory T cells (Tregs). Twenty‐four patients who were HLA‐A*24:02‐positive were enrolled and grouped into four cohorts of six patients each: cohorts 1, 2, 3, and 4 which received s.c. OCV‐C02 (emulsifying agent: Montanide™ ISA 51 VG) 0.3, 1, 3, and 6 mg/body, respectively. After cycle 1, patients who were eligible and willing to continue vaccination proceeded to the extended treatment period. No DLT occurred in cycle 1 and no major safety problems were reported throughout the trial. One patient in cohort 2, three patients in cohort 3 and two patients in cohort 4 achieved stable disease. CTL and DTH responses following vaccination were also observed across the four cohorts. OCV‐C02 at 0.3 to 6 mg/body was found to be safe and well tolerated. Trial registrations: JAPIC clinical trials registry (ID: JapicCTI‐132075) and ClinicalTrials.Gov (ID: NCT01801930).

show abstract

Section: Discussionsupporting

confidence: 91%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Phase 1 study of OCV‐C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

Vaccines for colorectal cancer: an update

Sarvizadeh

Ghasemi

Tavakoli

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Colorectal cancer (CRC) is known as the third most common and fourth leading cancer associated death worldwide. The occurrence of metastasis has remained as a critical challenge in CRC, so that distant metastasis (mostly to the liver) has been manifested in about 20%-25% of patients. Several screening approaches have introduced for detecting CRC in different stages particularly in early stages. The standard treatments for CRC are surgery, chemotherapy and radiotherapy, in alone or combination. Immunotherapy is a set of novel approaches with the aim of remodeling the immune system battle with metastatic cancer cells, such as immunomodulatory monoclonal antibodies (immune checkpoint inhibitors), adoptive cell transfer (ACT) and cancer vaccine. Cancer vaccines are designed to trigger the intense response of immune system to tumor-specific antigens. In two last decades, introduction of new cancer vaccines and designing several clinical trials with vaccine therapy, have been taken into consideration in colon cancer patients. This review will describe the treatment approaches with the special attention to vaccines applied to treat colorectal cancer. K E Y W O R D S colorectal cancer, exosome, therapy, vaccine J Cell Biochem. 2019;120:8815-8828.wileyonlinelibrary.com/journal/jcb

show abstract